Humana (HUM) AI Stock Analysis
Humana
(BMV:HUM)
No summary available
Humana (HUM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- MXN 52.08B
- Dividend Yield
- 0.85%
- Average Volume (3M)
- 7
- Price to Earnings (P/E)
- 41.8
- Beta (1Y)
- -0.29
- Revenue Growth
- 9.25%
- EPS Growth
- -17.56%
- Country
- Mexico
- Employees
- 67,060
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Plans
Humana Business Overview & Revenue Model
Company Description
Humana Inc., a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services...
Humana Earnings Call Summary
The call was strongly positive. Humana raised its 2026 EPS outlook, reported better-than-expected cost performance, delivered exceptional Stars results, expanded Medicaid and CenterWell membership, improved balance sheet efficiency, and expressed confidence in 2027 margin progress and its 2028 commitments. The main challenges were the continuing Stars headwind, higher expected 2027 cost trends, localized Primary Care Organization pressure, and uncertainty around AEP retention and the eventual size of the 2028 tailwind.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Humana raised its full year 2026 adjusted EPS outlook from at least $9 to at least $9.50 and expects to double its individual MA pretax margin this year, excluding the Stars headwind; for 2027, it anticipates membership will be up, expects fewer new members, and expects to make a material improvement on both a Stars adjusted and Stars unadjusted basis, reaching well into the profitability range, while 2027 trend is expected to be 8% to 9% versus 7% to 8% for 2026, with Part D expected to increase 14% to 15%. The company expects margin progression in '27 to put it on track for a 3% plus margin in 2028, expects a onetime tailwind in 2028, and said 95% of members in 4+ Star plans this year would be upside to its target; it expects to maintain top quartile results for BY '29, with key HEDIS metrics running roughly 5% ahead of last year's quality improvement rate on a per member basis, and said group MA improved 500 basis points excluding the Stars headwind. It also expects approximately 130 basis points of fourth-quarter GAAP debt-to-cap reduction and no substantial change in reinsurance use into 2027.
Humana Risk Analysis
Humana disclosed 16 risk factors in its most recent earnings report. Humana reported the most risks in the "Production" category.
Latest Risks Added
0 New RisksHumana Peers Comparison
Overall Rating
CI75Outperform
ELV69Neutral
CNC66Neutral
CVS64Neutral
UNH62Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CI | 75Outperform | $77.36B | 12.92 | 14.10% | 2.11% | 6.79% | -0.38% |
| ELV | 69Neutral | $91.96B | 18.13 | 11.59% | 1.61% | 3.60% | -4.06% |
| CNC | 66Neutral | $34.53B | 23.55 | 6.78% | ― | 9.71% | ― |
| CVS | 64Neutral | $107.28B | 9.68 | 14.13% | 3.17% | 6.77% | 2114.64% |
| UNH | 62Neutral | $353.17B | 22.50 | 16.35% | 2.30% | 3.33% | -8.75% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MX:HUM | Humana | 6967.90 | 2201.92 | 46.20% | |
| CNC | Centene | 69.74 | 35.49 | 103.62% | |
| CI | Cigna | 293.59 | 41.15 | 16.30% | |
| CVS | CVS Health Corp | 83.85 | 8.62 | 11.46% | |
| UNH | Unitedhealth Group Inc. | 394.15 | 80.91 | 25.83% | |
| ELV | Elevance Health, Inc. | 425.62 | 127.76 | 42.89% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.